NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Mercury Systems, Inc. (NASDAQGS: MRCY) Class Period: October 24, 2017 to April 24, 2018 Lead Plaintiff Deadline: September 10, 2018

Mercury Systems, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Mercury’s decision to in-source processing was adversely impacting Mercury’s operating margins and free cash-flow generation and conversion; (ii) Mercury’s model was becoming structurally more working capital intensive; (iii) as a result of the foregoing, Mercury’s public statements were materially false and misleading at all relevant times.

Get additional information about the MRCY lawsuit: http://www.kleinstocklaw.com/pslra-c/mercury-systems?wire=3

QUALCOMM Incorporated (NASDAQ: QCOM) Class Period: January 31, 2018 to March 12, 2018 Lead Plaintiff Deadline: August 7, 2018

The lawsuit alleges that QUALCOMM Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) Qualcomm had secretly filed a unilateral notice with CFIUS in order to frustrate Broadcom's attempt to acquire the Company; and (2) investors suffered damages as a result of defendants' wrongful acts and omissions. On March 5, 2018, Broadcom announced that Qualcomm had filed a voluntary request for The Committee on Foreign Investment in the United States to initiate an investigation into Broadcom’s actions. Broadcom referred to this as a “blatant, desperate act by Qualcomm to entrench its incumbent board of directors and prevent its own stockholders from voting for Broadcom’s independent director nominees.”

Get additional information about the QCOM lawsuit: http://www.kleinstocklaw.com/pslra-c/qualcomm...ted?wire=3

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 to July 9, 2018 Lead Plaintiff Deadline: September 17, 2018

The complaint alleges that during the class period ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Get additional information about the ACAD lawsuit: http://www.kleinstocklaw.com/pslra-c/acadia-p...inc?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com